BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome

StatusActive, Not Recruiting
PhasePhase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment closed, study ongoing Show 6 more changesShow less
    • Final enrollment: 12 participants (planned 24)
    • Primary completion date changed from estimate of Mar 17, 2026 to Oct 10, 2025
    • Study completion pushed from Jul 31, 2026 to Dec 31, 2026
    • Eligibility criteria expanded, about 37 words
    • Secondary endpoints: details revised at 2 of 8 entries
    • Site details revised
  2. Primary completion date: Feb 28, 2025 to Mar 17, 2026
    • Study completion date: Jul 31, 2025 to Jul 31, 2026
    v5
  3. Primary completion date: Jul 31, 2024 to Feb 28, 2025v4
  4. Start date changed from estimate of May 2023 to Feb 2, 2023v3
  5. Trial status: Not Yet Recruiting to Recruiting
    • Site details revised
    v2
  6. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this research study is to find the safest and most effective dose of the study drug, BXCL701, for the treatment of Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS). The names of the study drugs involved in this study are/is: * BXCL701
Trial Details
NCT Number NCT05703542
Lead Sponsor Eric Stephen Winer, MD
Conditions
(from sponsor)		 Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2
Related terms Leukemia, Myeloid, Acute
Enrollment 12 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov